A5004246651- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- Monoclonal and Polyclonal Antibodies Research
- Systemic Sclerosis and Related Diseases
- SARS-CoV-2 and COVID-19 Research
- Rheumatoid Arthritis Research and Therapies
- Chemokine receptors and signaling
- Salivary Gland Disorders and Functions
- Celiac Disease Research and Management
- Cytokine Signaling Pathways and Interactions
- Autoimmune and Inflammatory Disorders Research
- Peripheral Neuropathies and Disorders
- Chronic Lymphocytic Leukemia Research
- Viral Infections and Immunology Research
- Sarcoidosis and Beryllium Toxicity Research
- COVID-19 Clinical Research Studies
- Cytomegalovirus and herpesvirus research
- Mast cells and histamine
- Oral health in cancer treatment
- Head and Neck Cancer Studies
- Genetic Syndromes and Imprinting
- T-cell and B-cell Immunology
- dental development and anomalies
- Histiocytic Disorders and Treatments
- Oral Health Pathology and Treatment
Singapore General Hospital
2016-2025
Duke-NUS Medical School
2022-2023
Chinese Academy of Medical Sciences & Peking Union Medical College
2023
Vietnam National University, Hanoi
2023
Universidad de Antioquia
2023
Peking Union Medical College Hospital
2023
VNU University of Science
2023
Tan Tock Seng Hospital
2023
Teaching Hospital Kandy
2023
National University Hospital
2018
To assess the risk of flare and damage accrual after tapering glucocorticoids (GCs) in modified serologically active clinically quiescent (mSACQ) patients with systemic lupus erythematosus (SLE).
Assess whether treatment with probiotics improve gastrointestinal symptoms in patients systemic sclerosis (SSc). In this double-blind randomized placebo-controlled parallel-group phase II trial, SSc subjects total score ≥ 0.1 on a validated SSc-specific tract (GIT) questionnaire were (1:1) to receive 60 days of high dose multi-strain (Vivomixx® 1800 billion units/day) or identical placebo, followed by an additional both groups. Between group differences GIT change assessed after (primary...
Studies of flares autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination are limited by small sample size, short follow up or at risk selection bias.A national retrospective cohort study consecutive AIIRD patients ≥12 years old, across 8 hospitals who received least one dose a vaccine. Patients were included from the date 1st vaccine and censored time flare on clinic visit 3 months entry, whichever came first. Predictors determined Cox proportional hazards...
Abstract Objective Disease activity monitoring in SLE includes serial measurement of anti-double stranded-DNA (dsDNA) antibodies, but patients who are persistently anti-dsDNA positive, the utility repeated is unclear. We investigated usefulness testing predicting flare positive. Methods Data were analysed from a multinational longitudinal cohort with known results 2013 to 2021. Patients categorized based on their as negative, fluctuating or Cox regression models used examine associations...
Objective To assess whether Lupus Low Disease Activity State (LLDAS) attainment is associated with favorable outcomes in patients recent onset systemic lupus erythematosus (SLE). Methods Data from a 13-country longitudinal SLE cohort were collected prospectively between 2013 and 2020. An inception was defined based on disease duration < 1 year at enrollment. Patient characteristics noninception cohorts compared. Survival analyses performed to examine the association LLDAS damage accrual...
Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of in disease over time. Methods We analysed data from 2930 across 13 countries, collected 38 754 clinic visits 2013 2020. Clinic visit records were converted panel 1-year intervals. The time-adjusted mean activity, termed AMS , was calculated. yearly change <m:math xmlns:m="http://www.w3.org/1998/Math/MathML"...
Abstract Objective To determine prevalence and factors associated with flares post Coronavirus disease 2019 (COVID-19) mRNA vaccination in patients rheumatoid arthritis (RA), psoriatic (PsA) spondyloarthritis (SpA). Methods A retrospective multi-centre study was conducted (January 2021 to February 2022). Data were collected during index visit, defined as first post-vaccine visit which the patient had a physician-defined flare, or if at least 3 months elapsed since vaccine dose, whichever...
Objective To determine the efficacy of CXCL5 administration in lupus‐prone MRL/ lpr (Fas ) mice and elucidate its working mechanisms. Methods expression blood (obtained from SLE patients Fas mice) major internal organs was examined by Luminex, real‐time polymerase chain reaction, immunofluorescent staining analyses. Pharmacokinetic studies were performed healthy Institute Cancer Research mice. Efficacy demonstrated mice, mechanism treatment elucidated flow cytometry, RNA sequencing. Results...
Patients with cancer face an assault on oral health from their disease and accompanying treatment options are vulnerable to developing problems; therefore, the maintenance of is particularly important. A study was carried out in one oncology unit within a large teaching hospital measure extent problems patients, current mouth care practices, staff knowledge. The findings showed that were common, but were: (1) underreported by patients (2) underdiagnosed doctors nurses (3) inadequately...
Aims: Aberrant immune cell activation characterises SLE, in which glucocorticoids (GCs) remain a cornerstone of treatment.However, the unacceptable side effects GCs have created pressing need for similarly broad-acting, but safer, anti-inflammatory agent.The glucocorticoidinduced leucine zipper, GILZ, mediates is independent GC-associated metabolic adverse effects.Previously, we showed that GILZ suppressed permitting inappropriate activation.Therefore, restoring promising therapeutic...
<h3>Background</h3> The Asia-Pacific League of Associations for Rheumatology (APLAR) recently published consensus recommendations, including overarching principles, general management, and specific treatment strategies SLE in Asia. use hydroxychloroquine (HCQ) all patients was recommended unless contraindicated (statement 7).<sup>1</sup> We evaluated the current therapeutic practice with respect to anti-malarial Asia Pacific region against this recommendation. <h3>Methods</h3> used data from...
Nail-patella syndrome (NPS), also known as hereditary onycho-osteodystrophy (HOOD) is a rare inherited autosomal dominant disease with involvement of the LMX1 gene. We report case NPS atypical lip, palate, and lung discuss possible genetic associations between NPS, recurrent pneumothoraces, cleft lip/palate.
<h3>Background</h3> Systemic Lupus Erythematosus (SLE) immunopathogenesis involves a complex network of regulatory and effector cells with its balance constituting an immune rheostat that maintains homeostasis. Thus, the disease must be interrogated holistically to identify mechanistically clinically relevant cell subsets for pathogenesis. There is crucial unmet need examine mechanism tolerance loss in lupus novel targets potential therapeutic intervention improve outcomes....
Abstract Objective High disease activity status (HDAS) in patients with systemic lupus erythematosus (SLE) is associated adverse long-term outcomes. We examined the frequency of low state (LLDAS) and remission (REM) attainment HDAS whether their was improved patient Methods Demographic, clinical outcomes data, collected prospectively from a multinational cohort between 2013 2020, were analysed. Disease assessed using SLEDAI-2K. defined as SLEDAI-2K ≥ 10. Patients’ first visit 10 assigned...
In trials of systemic lupus erythematosus (SLE), the SLE Responder Index (SRI) is most commonly used primary efficacy end point but has limited validation against long-term outcomes. We aimed to investigate associations attainment a modified version SRI (mSRI) with key clinical outcomes in patients up 5 years follow-up.We data from large multicenter, longitudinal cohort which received standard care. The first visit active disease (defined as Disease Activity 2000 [SLEDAI-2K] score ≥6) was...
Background: Patients with systemic lupus erythematosus (SLE) suffer from severe morbidity and mortality 1-4 , either the disease itself or side effects of immunosuppression 5 . Discovery novel effective therapies less toxicity is an urgent need. Objectives: The aim this study to elucidate therapeutic potential working mechanism cytokine CXCL5 in mice. Methods: Treatment CXCL5, bone marrow (BM)-MSCs, standard care (SOC) combination methylprednisolone cyclophosphamide was given 16-week-old Fas...
<b>Background:</b> Erdheim-Chester disease (ECD) is a rare, non-Langerhans cell histiocytosis with multisystem involvement. Its protean manifestations and mimicry of several neoplastic inflammatory conditions often lead to late diagnosis, when severe functional impairment or life-threatening has occurred. Prognosis remains poor, although published data on the use interferon α (IFN-α) BRAF inhibitors have expanded therapeutic options. <b>Objective:</b> To compare patterns presentation factors...
Abstract Objective To determine prevalence and factors associated with flares post Coronavirus disease 2019 (COVID-19) mRNA vaccination in patients rheumatoid arthritis (RA), psoriatic (PsA) spondyloarthritis (SpA). Methods A retrospective multi-centre study was conducted (January 2021 to February 2022). Data were collected during index visit, defined as first post-vaccine visit which the patient had a physician-defined flare, or if at least three months elapsed since vaccine dose, whichever...
<h3>Background</h3> Systemic lupus erythematosus (SLE) is a complex, systemic autoimmune disease. Disease presentation heterogeneous and characterized by alternating flares remissions. Recent treatment developments have been made with FDA approval of anifrolumab for adult SLE in 2021 <sup>[1]</sup> but there are many patients inadequate therapeutic response. Furthermore, lack specific molecular targets, current therapy relies mainly on general immunosuppression. This can adversely affect...
<h3>Background</h3> Lupus Low Disease Activity State (LLDAS) permits serological activity and in several organs including joint, muscle, mucocutaneous activity, provided SLEDA4-2K is <=4 other LLDAS criteria are met. <h3>Methods</h3> Patients the Asia-Pacific Collaboration cohort who were recruited followed up between 2013 2020 had been at least once included. However, visits which fulfilled both DORIS remission was excluded. Multivariable Cox regression used to compare flare (SELENA...
<h3>Background</h3> The development of lupus low disease activity state (LLDAS) as a treat-to-target endpoint for SLE patients has been validated. Its attainment associated with improved outcomes. This study aims to show whether machine learning model can yield good results in predicting patient will achieve LLDAS on their succeeding assessment. <h3>Methods</h3> A total 42,355 records were retrieved from the APLC longitudinal database. Three models – XGBoost, Random Forest, and Naive Bayes...